Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Imran, Mohd; Alshrari, Ahmed Subeh; Asdaq, Syed Mohammed Basheeruddin; Abida, Abida

doi:10.1016/j.jiph.2021.06.013

Cited by 26 publications

(31 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the availability of biochemical assays accelerates the development of RdRp inhibitors [ 12 , 13 , 14 , 15 , 16 ]. Two RdRp inhibitors, remdesivir (anti-Ebola virus experimental drug) [ 8 ] and favipiravir (anti-influenza drug) [ 9 ] have already been approved for COVID-19 treatment ( Table 1 ). Both these broad-spectrum antiviral drugs have been shown to reduce the progression of COVID-19 and associated clinical symptoms along with a substantial decrease in recovery time [ 17 , 18 , 19 ].…”

Section: Rna-dependent Rna-polymerase (Rdrp)mentioning

confidence: 99%

“…The manufacturing process is related to the cost of the marketed medicine. A costly manufacturing process may increase the price of the medicine [ 8 ]. Therefore, the pharmaceutical industries always try to develop a cost-effective process for manufacturing a drug.…”

Section: Expert Opinionmentioning

confidence: 99%

“…One patent application related to the transmucosal solid dosage (sublingual tablet) form of molnupiravir has been filed. The authors trust that this application may be useful for an injectable drug, like remdesivir [ 8 ], and will not bring any advantageous effect to molnupiravir, which is already an orally active drug. The patent search also provided some patent applications related to new compounds, isolated antibodies, polypeptide, and hydrolyzable tannin that have been claimed to treat COVID-19 in combination with molnupiravir.…”

Section: Expert Opinionmentioning

confidence: 99%

“…If we trust the news on social media, then molnupiravir approval is closer in India and Australia. The USFDA has already approved injectable monoclonal antibodies [67] and intravenous remdesivir [8] as COVID-19 treatments. Therefore, oral treatment for non-hospitalized COVID-19 patients will be an advantage.…”

Section: Expert Opinionmentioning

confidence: 99%

“…Vaccines and antiviral drugs are important means of preventing and treating COVID-19. However, as of now only a few antiviral treatments are available for COVID-19 [ 5 , 6 , 7 , 8 , 9 ]. Even vaccinated people have been infected with SARS-CoV-2, millions of immunocompromised patients may not get full protection after vaccination, and the existing vaccines may not be effective against the new variants of SARS-CoV-2 [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Imran

Arora

Asdaq³

et al. 2021

Molecules

Self Cite

153

157

View full text Add to dashboard Cite

The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.

show abstract